Global Blood Therapeutics Inc (NASDAQ:GBT)
| 59.23 BATS BZX Real-Time Price As of 11:39am ET |  -2.06 / -3.36%Today’s Change | 39.95 Today|||52-Week Range 87.54 | -25.49% Year-to-Date |
Latest GBT News | Press Releases
| Don't buy the stock market hype around coronavirus vaccine and treatment companies Oct 14 / CNN.com - Paid Partner Content |
Today’s Trading
| Previous close | 61.29 |
| Today’s open | 59.15 |
| Day’s range | 58.20 - 63.09 |
| Volume | 5,872 |
| Average volume (3 months) | 833,190 |
| Market cap | $3.9B |
Data as of 11:39am ET, 10/20/2020
Growth & Valuation
| Earnings growth (last year) | -34.31% |
| Earnings growth (this year) | +24.12% |
| Earnings growth (next 5 years) | 0.00% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | 2,199.23 |
| Price/Book | 6.59 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TGTXTG Therapeutics Inc | -0.59 | -2.00% |
| INSMInsmed Inc | +0.91 | +2.43% |
| RETAReata Pharmaceutical... | +1.56 | +1.38% |
| CCXIChemoCentryx Inc | -0.92 | -1.71% |
Data as of 11:40am ET, 10/20/2020
Financials
| Next reporting date | November 4, 2020 |
| EPS forecast (this quarter) | -$0.75 |
| Annual revenue (last year) | $2.1M |
| Annual profit (last year) | -$266.8M |
| Net profit margin | -12,654.93% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters South San Francisco, California |
Forecasts
